抗CD19 CAR T细胞联合依鲁替尼治疗慢性淋巴细胞白血病
这项前瞻性单中心2期试验在≥6个月依鲁替尼治疗后未达完全缓解的慢性淋巴细胞白血病患者中,将自体抗CD19人源化结合域T细胞(huCART-19)加入依鲁替尼。20例入组患者中19例接受输注,3个月完全缓解率为44%(90%CI 23-67%),12个月时72%受检者无可测量残留病,48个月总生存率和无进展生存率估计分别为84%和70%。
要点
- ≥6个月依鲁替尼未达完全缓解的CLL患者中,加用huCART-19获得高比例深度持久缓解。
- 18例发生细胞因子释放综合征(15例为1-2级),5例发生神经毒性(4例1-2级,1例4级)。
- 3个月完全缓解率44%(90%CI 23-67%),12个月时72%受检者无可测量残留病。
核心结论
- 在≥6个月依鲁替尼治疗后未达完全缓解的慢性淋巴细胞白血病患者中,加用huCART-19介导了高比例的深度且持久缓解。
研究设计与样本
- 前瞻性单中心2期试验,入组20例,19例接受自体抗CD19人源化结合域T细胞(huCART-19)输注。
- 主要终点为安全性、可行性及3个月内达到完全缓解。
- 所有输注患者中位随访41个月(范围0.25-58个月)。
主要发现
- 18例发生细胞因子释放综合征,其中15例为1-2级;5例发生神经毒性,其中4例为1-2级,1例为4级。
- 国际CLL工作组(iwCLL)可评估患者的3个月完全缓解率为44%(90%CI 23-67%)。
- 12个月时,72%的受检患者无可测量残留病。
- 48个月时估计总生存率为84%,无进展生存率为70%。
- 3或6个月时无可测量残留病的15例患者中,13例在末次随访时仍处于持续完全缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In chronic lymphocytic leukemia (CLL) patients who achieve a complete remission (CR) to anti-CD19 chimeric antigen receptor T cells (CART-19), remissions are remarkably durable. Preclinical data suggesting synergy between CART-19 and the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib prompted us to conduct a prospective single-center phase 2 trial in which we added autologous anti-CD19 humanized binding domain T cells (huCART-19) to ibrutinib in patients with CLL not in CR despite ≥6 months of ibrutinib. The primary endpoints were safety, feasibility, and achievement of a CR within 3 months. Of 20 enrolled patients, 19 received huCART-19. The median follow-up for all infused patients was 41 months (range, 0.25-58 months). Eighteen patients developed cytokine release syndrome (CRS; grade 1-2 in 15 of 18 subjects), and 5 developed neurotoxicity (grade 1-2 in 4 patients, grade 4 in 1 patient). While the 3-month CR rate among International Working Group on CLL (iwCLL)-evaluable patients was 44% (90% confidence interval [CI], 23-67%), at 12 months, 72% of patients tested had no measurable residual disease (MRD). The estimated overall and progression-free survival at 48 months were 84% and 70%, respectively. Of 15 patients with undetectable MRD at 3 or 6 months, 13 remain in ongoing CR at the last follow-up. In patients with CLL not achieving a CR despite ≥6 months of ibrutinib, adding huCART-19 mediated a high rate of deep and durable remissions. ClinicalTrials.gov number, NCT02640209.
引用
- Gill S, Vides V, Frey NV, et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 2022. PMID: 35349631. doi:10.1182/bloodadvances.2022007317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。